One of the biggest debates in addiction medicine is over methadone. Will Congress or the Biden administration make it more accessible?December 29, 2023Check out STAT+Sponsored By Christine Kao/STAT Fights over methadone, harm reduction, and more: 3 addiction stories to watch in 2024 One of the biggest debates in addiction medicine is over methadone. Will Congress or the Biden administration make it more accessible? By Lev Facher Opinion: There's a less intimidating alternative to EpiPens for dangerous allergic reactions. Why won't the FDA approve it? With alternatives available, no one should have to live in fear of needles, and no one should lose their life due to anaphylaxis. By Eleanor Garrow-Holding We wish we'd written that: STAT staffers share their favorite stories of 2023 Our staff looks with admiration — and some envy — to journalists doing great reporting on chronic disease, health policy, and addiction. By STAT Staff Andrew Harnik/AP Opinion: Buprenorphine, autism diagnoses, and long Covid: the most-read First Opinion essays of 2023 The most popular 2023 First Opinions look at opioid use, autism, waiving residency requirements for doctors who trained overseas, and more. By Torie Bosch More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Daily Recap? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments